Product Information
CARBIDOPA-LEVODOPA 25-100 TAB is a generic product labeled by Camber Pharmaceuticals Inc., priced at $0.0759 per EA under NDC 31722038210. Its NADAC has been published 57 times since Sep 3, 2025.
FDA first approved this application on Jan 14, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25; 100 mg/1; mg/1
Manufacturer
Camber Pharmaceuticals Inc.NDC
31722038210
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CARBIDOPA; LEVODOPAApproval Type
Generic (ANDA)
FDA Application
ANDA218939FDA Approved
1/14/2025
TE Code
AB
On Market Since
5/27/2025
Pharmacological Classes
Price Statistics
The NADAC for CARBIDOPA-LEVODOPA 25-100 TAB has been published 57 times since Sep 3, 2025, and over the history we have for it it has declined 13.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0759 per EA |
|---|---|
| All-time high | $0.0876 (Sep 10, 2025) |
| All-time low | $0.0719 (May 20, 2026) |
| 52-week high | $0.0818 |
| 52-week low | $0.0719 |
| Median price | $0.0765 |
| Average price | $0.0768 |
| Largest weekly change | -6.6% (Sep 17, 2025) |
| Weeks tracked | 57 |
| Tracking since | Sep 3, 2025 |
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Camber Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Carbidopa and Levodopa market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aromatic Amino Acid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CARBIDOPA-LEVODOPA 25-100 TAB?
The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVODOPA 25-100 TAB, manufactured by Camber Pharmaceuticals Inc., is $0.0759 per EA (NDC 31722038210), effective Sep 30, 2026.
How has the price of CARBIDOPA-LEVODOPA 25-100 TAB changed over time?
Over the history we have for it, the NADAC for CARBIDOPA-LEVODOPA 25-100 TAB has declined 13.4%. It has been tracked across 57 weekly CMS publications since Sep 3, 2025.
What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVODOPA 25-100 TAB?
Since Sep 3, 2025, the NADAC for CARBIDOPA-LEVODOPA 25-100 TAB has ranged from a low of $0.0719 (May 20, 2026) to a high of $0.0876 (Sep 10, 2025), with a median of $0.0765 per EA.
Are there cheaper alternatives to CARBIDOPA-LEVODOPA 25-100 TAB?
9 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CARBIDOPA-LEVODOPA 25-100 TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures CARBIDOPA-LEVODOPA 25-100 TAB?
CARBIDOPA-LEVODOPA 25-100 TAB (NDC 31722038210) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.